Trial Profile
Study of abiraterone or enzalutamide following docetaxel chemotherapy in the hormone-sensitive setting in castration-resistant prostate cancer patients
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 28 Jun 2018
Price :
$35
*
At a glance
- Drugs Abiraterone (Primary) ; Enzalutamide (Primary) ; Docetaxel
- Indications Prostate cancer
- Focus Therapeutic Use
- 28 Jun 2018 New trial record
- 05 Jun 2018 Results presented at the 54th Annual Meeting of the American Society of Clinical Oncology